Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-04-18
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?MLTX — MoonLake Immunotherapeutics
NASDAQ · Biotechnology · Biotechnology
$17.18+11.99%Market cap1.25B
- Latest Close
- $17.18
- 30-Day Move
- +12.0%
- Market Cap
- $1.2B
- Shares Outstanding
- 71,730,000
- P/B Ratio
- 7.74
- ROE
- -26.6%
Analyst consensus: Buy · 23 analysts
NASDAQ:MLTXBiotechnology / BiotechnologyDelayed public snapshot
MoonLake Immunotherapeutics
A read-only Alphactor snapshot forMoonLake Immunotherapeutics. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$17.18
30-Day Move
+12.0%
Market Cap
$1.2B
Shares Outstanding
71,730,000
P/B Ratio
7.74
ROE
-26.6%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$17.18
+12.0%last 90 delayed daily bars
Market cap$1.2B
90D High
$19.73
90D Low
$11.06
Avg Volume
1,748,343
What stands out
MLTX is up 12.0% over the last 30 trading days shown on this page.
Latest operating income is $-65M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
21.2%
Fundamentals snapshot
Latest Close
$17.18
30-Day Move
+12.0%
Market Cap
$1.2B
Shares Outstanding
71,730,000
P/B Ratio
7.74
ROE
-26.6%
ROA
-24.9%
Debt / Equity
0
Current Ratio
21.55
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-65M
Net Income
$-62M
Gross Margin
--
Net Margin
--
Current Ratio
21.55
Debt / Equity
0.00
Quality snapshot
Altman Z
3.86
Safe
Piotroski
1
Weak (0-3)
Cash Conversion
0.86x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-65M | $-50M | $-56M |
| 2023-12-31 | $0 | $-54M | $-36M | $-43M |
| 2024-12-31 | $0 | $-143M | $-119M | $-117M |
| 2025-12-31 | $0 | $-245M | $-227M | $-196M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-04-07
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-28
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/investing.ico', homepage_url='https://www.investing.com/', logo_url='https://s3.massive.com/public/assets/news/logos/investing.png', name='Investing.com')•2026-02-04
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward ProfilePublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-02-02
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor DayAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 742,022 | 0.01% | 2025-12-31 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 375,988 | 0.01% | 2025-12-31 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Glob | 226,850 | 0.00% | 2025-12-31 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 143,558 | 0.00% | 2026-02-28 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Small-Cap Equity Fund | 112,379 | 0.00% | 2025-12-31 |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 96,424 | 0.00% | 2025-11-30 |
| iShares Trust-iShares ESG Aware MSCI USA Small-Cap ETF | 86,030 | 0.00% | 2026-02-28 |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 80,000 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
T. Rowe Price
Filed 2025-11-14
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
Citadel Advisors
Filed 2025-08-14
$79M
--
D.E. Shaw
Filed 2026-02-17
$33M
+2587.7%
BlackRock
Filed 2024-05-10
$21M
--
Vanguard Group
Filed 2025-08-11
$6M
+6.0%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
23
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.